What KPV / TA-1 / LL-37 Blend actually is

This blend stacks three immune peptides with complementary mechanisms: KPV (α-MSH 11-13 tripeptide, anti-inflammatory), Thymosin Alpha-1 (T-cell maturation and Th1 differentiation), and LL-37 (cathelicidin antimicrobial and biofilm disruption).¹

The combination addresses inflammation, adaptive immune function, and direct antimicrobial activity in a single protocol — useful in patients with recurrent infections, biofilm-associated presentations, or comprehensive immune support goals.²

At Luxbae, KPV / TA-1 / LL-37 Blend is prescribed and supervised by Dr. Ernst von Schwarz, MD, PhD after a complimentary medical consultation.

Mechanism — Three immune axes

KPV (anti-inflammatory NF-κB modulation), TA-1 (adaptive T-cell function), LL-37 (innate antimicrobial and biofilm).¹

What the research shows

Comprehensive immune coverage. Three peptides addressing different immune axes.

Anti-inflammatory dimension. KPV’s mucosal anti-inflammatory effect.¹

Adaptive immune support. TA-1’s T-cell and Th1 effects.²

Side effects: Injection-site reactions, transient flu-like symptoms (immune activation), occasional headache.

FDA note: None of the components is FDA-approved as a US blend; prescribed under medical supervision.

KPV / TA-1 / LL-37 Blend FAQ

Better than single peptides?
For multifactorial immune presentations — yes. For specific single goals, standalone components may suffice.

Cycle length?
Typically 4–8 weeks.

References

1. Goldstein AL. Thymosin alpha 1 clinical applications. Expert Opin Biol Ther. 2009;9(5):593-608.
2. Vandamme D, et al. LL-37 comprehensive summary. Cell Immunol. 2012;280(1):22-35.
3. Brzoska T, et al. Alpha-MSH-related tripeptides. Endocr Rev. 2008;29(5):581-602.